Henlius Pursues Two-Pronged Approach In Quest For Novel ADCs
Partnering And Independent
Moving decisively but not hurriedly, Henlius is taking a two-pronged approach to join the global ADC race. The first two molecules developed via its in-licensed novel linker-payload platform have entered the clinical stage, while its own proprietary programs are seeing steady R&D progress, the Chinese firm's head of early R&D tells Scrip in an interview.
You may also be interested in...
The combination of Astellas and Seagen's antibody-drug conjugate Padcev and Merck & Co's checkpoint inhibitor Keytruda has shown improvements in survival not previously achieved in a broad population of patients with advanced urothelial carcinoma.
Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.
China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.